What Should we do When HIV-Positive Children Fail First-Line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies. by Patten, Gabriela et al.
1 
 
The Pediatric Infectious Disease Journal Publish Ahead of Print 
DOI: 10.1097/INF.0000000000002156 
What Should we do When HIV-Positive Children Fail First-Line Combination 
Antiretroviral Therapy? A Comparison of 4 ART Management Strategies 
Gabriela Patten, MSc
1
, Michael Schomaker, Dr. rer. nat.
1
, Mary-Ann Davies, PhD
1
, Helena 
Rabie
2
, Gert van Zyl, PhD
3
, Karl Technau, MSc (Med)
4
, Brian Eley, MBChB
5
, Andrew Boulle, 
PhD
1
, Russell B. Van Dyke, MD
6
, Kunjal Patel, DSc
7
, Nosisa Sipambo, MBBCH
8
, Robin Wood, 
DSc (Med)
9
, Frank Tanser, PhD
10
, Janet Giddy, MFamMed
11
, Mark Cotton FCPaed, (SA)
12
, 
James Nuttall, MSc (Med)
5
, Gadija Essack, MBChB
2
, Brad Karalius, MPH
7
,  George Seage, lll 
DSc
7
, Shobna Sawry, MSc
13
, Matthias Egger, MD
1,14
, and Lee Fairlie, MBChB
13
,
 
for IeDEA 
Southern Africa 
Abbreviated title: Comparing strategies for children failing ART 
Running head title: Managing HIV-positive children failing ART 
Corresponding author:  Gabriela Patten, Address: Centre for Infectious Disease Epidemiology 
& Research, School of Public Health & Family Medicine, Faculty of Health Sciences, University 
of Cape Town, Anzio Road, Observatory 7925 South Africa. Email: gem.patten@uct.ac.za 
Ph:    +27 21 406 6482 Fax:  +27 21 406 6764 Cell:  +27 78 135 4333 
1
Centre for Infectious Disease Epidemiology & Research, University of Cape Town, Cape Town, 
South Africa; 
2
Tygerberg Academic Hospital, University of Stellenbosch; 
3
Division of Medical 
Virology, Stellenbosch University and National Health Laboratory Service, Tygerberg, Cape 
Town, South Africa;  
4
University of the Witwatersrand, Department of Paediatrics and Child 
Health, Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa, 
5
Red Cross War 
Memorial Children’s Hospital, and the Department of Paediatrics and Child Health, University 
AC
CE
PT
ED
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
11
93
33
 
| 
do
wn
lo
ad
ed
: 
6.
1.
20
20
2 
 
of Cape Town, Cape Town, South Africa; 
6
Department of Pediatric, Tulane University, School 
of Medicine, New Orleans, United States; 
7
Harvard T.H. Chan School of Public Health, 
Department of Epidemiology, Centre for Biostatistics in AIDS Research (CBAR), Boston, 
United States; 
8
University of the Witwatersrand, Department of Paediatrics and Child Health, 
Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa; 
9
The Desmond Tutu 
HIV Centre, Institute for Infectious Disease & Molecular Medicine, University of Cape Town, 
Cape Town, South Africa; 
10
Africa Centre for Health and Population Studies, University of 
KwaZulu-Natal, Mtubatuba, South Africa; 
11
McCord Hospital, Durban, South Africa; 
12Stellenbosch University and Tygerberg Children’s Hospital, Department of Paediatrics and 
Child Health Division of Paediatric Infectious Diseases, Cape Town, South Africa; 
13
Wits 
Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South 
Africa; 
14
Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, 
Switzerland 
Conflicts of Interest and Sources of Funding: This study was supported by funding from the 
United States National Institutes of Health Grant 5U01AI069924. ME is supported by the Swiss 
National Science Foundation, grant 32FP30-174281. The authors declare that there are no 
conflicts of interest. 
Acknowledgements 
Lucy Profitt for her initial work on this concept. 
 
  AC
CE
PT
ED
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
3 
 
Abstract 
Background 
Managing virologic failure (VF) in HIV-infected children is especially difficult in resource-
limited settings, given limited availability of alternative drugs, concerns around adherence and 
the development of HIV resistance mutations. We aimed to evaluate four management strategies 
for children following their first episode of VF by comparing their immunologic and virologic 
outcomes. 
Methods 
We included children (aged <16 years) with VF from 8 IeDEA-SA cohorts, initiating cART 
between 2004-2010, who followed one of four management strategies: continuing on their 
failing regimen; switching to a second-line regimen; switching to a holding regimen (either 
lamivudine monotherapy or other non-cART regimen); discontinuing all ART. We compared the 
effect of management strategy on the 52-week change in CD4% and log10VL from VF, using 
inverse probability weighting of marginal structural linear models.   
Results 
982 patients were followed over 54168 weeks.  Relative to remaining on a failing regimen, 
switching to second-line showed improved immunologic and virologic responses 52 weeks after 
VF with gains in CD4% of 1.5% (95% CI 0.2-2.8) and declines in log10VL of -1.4 copies/mL 
(95% CI -2.0, -0.8), whilst switching to holding regimens or discontinuing treatment had worse 
immunologic (-5.4% (95% CI -12.1, 1.3) and -5.6% (95% CI -15.4, 4.1)) and virologic outcomes 
(0.2 (95% CI -3.6, 4.1) and 0.8 (95% CI -0.6, 2.1) respectively. 
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Conclusions 
The results provide useful guidance for managing children with VF. Consideration should be 
given to switching children failing first-line cART to second-line, given the improved virologic 
and immune responses when compared with other strategies.   
Key Words: HIV, virologic failure, second-line, resource-limited settings, adherence 
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Introduction 
By 2015 nearly 900 000 HIV-positive children were receiving combination antiretroviral therapy 
(cART),(1) most of whom are in sub-Saharan Africa. The shift to early cART initiation, results 
in HIV-infected children being on treatment for long durations, and virologic failure (VF) is a 
concern; an estimated 20% of children developing VF after 3 years of cART.(2) With limited 
alternative treatment options, and the difficulties of sustained adherence in this vulnerable group, 
managing VF in children in resource-limited settings (RLS) is particularly challenging. 
Adherence is especially difficult for children due to their dependence on caregivers for cART 
administration, difficulties facing families in disclosing HIV status to their child, the effects of 
HIV-associated stigma, and pharmaceutical challenges with pediatric drug formulations, dosing 
and drug-drug interactions.(3) Adolescents face their own adherence barriers, including the 
emotional challenges of puberty, and disclosing their HIV-status to others.(4)   
Access to pediatric second- or third-line regimens is frequently restricted in RLS, where some 
newer drugs such as dolutegravir still require dosing studies and registration. Hence the optimal 
management of children with VF and suspected or proven poor adherence is challenging; 
switching to a new regimen risks increasing resistance mutations if adherence is not assured. 
Delays in switching patients from failing regimens are common, but have negative 
consequences.(2, 5) The South African national guidelines recommend careful assessment of 
adherence among children with VF before switching to second-line, and suggest “holding 
strategies” for those with ongoing adherence challenges.(6) “Holding regimens”, such as 
lamivudine monotherapy (LM) may retain HIV variants with reduced viral fitness, particularly 
the M184V mutation, slowing immune decline whilst ensuring no new drug resistance 
develops.(7-9) Complete treatment interruption may also allow adherence barriers to be 
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addressed without new drug resistance emerging.(10) There is little evidence weighing the 
relative benefits and risks of these different strategies following VF in children. Fairlie et al. 
compared four management strategies following the most recent episode of VF, in an 
observational study from US-based pediatric cohorts,(11) but no comparative study has yet been 
done in RLS in sub-Saharan Africa, or following the first episode of VF. 
Using causal inference methods and observational data from over 14,000 children in the 
International epidemiologic Database to Evaluate AIDS (IeDEA) Southern Africa, we compared 
immunologic and virologic outcomes after VF for those managed with the following strategies: 
switching to second-line cART, continuing on failing first-line cART, switching to non-cART 
holding regimens, and discontinuing all antiretrovirals.   
Methods 
We included data collected prospectively from eight IeDEA cohorts in South Africa. IeDEA is a 
multi-regional collaboration of HIV cohort studies.(12) Each study site had institutional ethical 
approval to contribute data to IeDEA analyses. Children (<16 years) initiating cART from 2004 
to 2010, with documented VF after at least six months on cART were included. Final database 
closure was June 2012. 
All study sites are part of the South African national ART program where virologic monitoring is 
routinely used. Table 1 provides details of the recommended first-line regimens during the study 
period.(13-15) The recommended second-line regimen prior to 2010 was to switch from an 
efavirenz-based to a lopinavir/ritonavir(LPV/r)-based regimen and switch at least one nucleoside 
reverse transcriptase inhibitor (NRTI).  Prior to 2010, children failing protease-inhibitor (PI)-
based first-line were switched to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based 
cART. From 2010 guidelines recommended specialist referral for children failing PI-based 
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regimens as they require resistance testing and potentially integrase inhibitors, second generation 
PIs or NNRTIS such as darunavir and etravirine.(13)  
We defined virologic failure (VF) as having at least two consecutive viral loads (VL) >1000 
copies/ml, measured at least one month and less than one year apart.  The date of VF was the 
date of the second unsuppressed VL. We considered only the first episode of VF. 
We defined cART as comprising at least three antiretroviral drugs from at least two different 
drug classes. We compared four management strategies:  
 Remaining on a failing first-line regimen, with at most one single drug substitution not 
constituting a drug class change. 
 Switching to second-line: changing at least one drug including a change in drug class. 
 Switching to a holding regimen: a regimen not meeting the definition of cART, such as 
one or more drugs from a single class, or only two drugs from two drug classes. 
 Treatment interruption (TI): discontinuing all antiretroviral drugs. 
The outcomes were the CD4% and log10VL slope, which were calculated at each time point after 
VF with a recorded CD4% or log10VL measure, as the difference between the current CD4%/ 
log10VL and the CD4%/ log10VL at VF, divided by the time in weeks between these two 
measurements.  Patients were censored for death, transferring care or loss to follow-up (nine 
months without a recorded clinic visit prior to database closure).  
Outcomes were modelled based on follow-up time on each strategy. Initially, we derived 
unweighted linear regression models for each outcome, adjusting for management strategy 
(allowing a four week lag to ensure the outcome reflected the appropriate strategy), covariates at 
VF, and weeks since failure. To estimate the effect of management strategy on the outcomes we 
adjusted for the time-dependent confounders VL and CD4%, which may have influenced both 
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clinician choice of management strategy and the respective outcome, using inverse probability of 
treatment weighting (IPTW) of marginal structural linear models.(16) To estimate the IPTW, we 
fitted a pooled multinomial logistic regression model for management strategy choice until a 
switch to second-line was made.(17) We used different model specifications, based on 
in/exclusion of variables, interaction terms, and the functional form of the variables. All models 
used stabilized weights as previously described.(17) We chose the final model based on Bayesian 
model averaging and the stability of the weights.(18)  The final marginal structural model was a 
linear model with the slope of CD4% or log10VL (from VF to the current time point) as the 
outcome, weights to adjust for the confounding, and conditional on time and covariates at VF, 
including immune suppression, age, VL, being on a PI-based regimen and level of care.  The 
stabilized weights had a mean of 1.008, minimum of 0.000924 and maximum of 12.2686.  
Results 
Across the eight sites, 1,347 (19%) of 7,053 children with recorded VL measurements on cART 
experienced VF, and 365 were excluded due to incomplete CD4% and regimen data. The final 
dataset comprised 982 children (46% female), with median age at VF of 6.1 years (IQR 2.7-
10.7), and median duration on cART of 1.4 years (Table, Supplemental Digital Content 1, 
http://links.lww.com/INF/D231). Median time between first and second consecutive VL >1000 
was 90 days (IQR 66-140). Comparing patients based on their first change in management 
strategy, 557 (57%) remained on failing regimens throughout follow-up, 335 (34%) switched to 
second-line, 25 (3%) switched to holding regimens and 65 (7%) interrupted treatment. Most 
patients (95%) changed strategies only once. Among those switched to holding regimens, 80% 
were placed on NRTI-only regimens. Children switched to second-line were older, had lower 
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median CD4% at cART start, at failure and lower nadir CD4%. Few patients (32/398, 8%) on PI-
based first-line were switched to NNRTI-based second-line.  
At study closure, 9 (1%) patients had died (all having remained on their failing regimen), 216 
(22%) transferred care, 90 (9%) were lost to follow-up (88 having remained on their failing 
regimen, 1 after switch to second-line and 1 after TI), and 667 (68%) remained in care at their 
original treatment site. Figure 1 shows management strategies at five points during the 52-week 
study period, 73% of follow-up time was spent on failing regimens, 24% on second-line, 1% on 
holding regimens, and 2% interrupting treatment.  Median time to first change in strategy was 
168 days (IQR 79-365), with median time from VF to second-line 115 days (IQR 62-203), to 
holding regimens 90 days (IQR 30-154), and to TI 123 days (IQR 52-259). 
Choice of management strategy 
Choice of management strategy was strongly associated with type of regimen at failure. 
Compared to those on PI-based first-line, those on NNRTI-based regimens were more likely to 
switch strategies than remain on failing first-line (Table 2). Those with the highest VL at VF 
(VL>50,000 copies/ml), were more likely to interrupt treatment (aHR 5.9, 95% CI 2.5, 13.8). 
Having a mid-range VL at VF (10,000-50,000 vs 1,000-5,000copies/ml) was associated with 
switching to a holding regimen (aHR 2.7, 95% CI 1.1, 7.0), indicating clinician preference to 
switch partially adherent patients to this strategy.  
Outcomes: Change in CD4% and VL 
Figure 2A and 2B shows the model estimates for the difference in mean 52-week change in 
CD4% and log10VL after VF, relative to remaining on a failing regimen and switching to second-
line respectively.  The final weighted model indicates that switching to second-line, even after 
operational delay, results in increases in CD4% and declines in VL compared to remaining on a 
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failing regimen.  Switching to a holding regimen or interrupting treatment results in declines in 
CD4% and increases in VL, albeit with wide confidence intervals. 
We conducted a separate analysis restricted to children on NNRTI-based first-line, for whom 
alternative regimens at the time were more robust than for those failing PI-based first-line 
(Figures 2C and 2D).  Overall, the results were similar except the estimated declines in CD4% 
for those interrupting treatment compared to switching to second-line were significant and much 
larger than for all patients. When we compared switching to a holding regimen relative to TI we 
found that those interrupting treatment experienced bigger declines in CD4% (-12.1, 95% CI -
29.1; 4.9). Due to small numbers switching to second-line NNRTI from a PI-based first-line, we 
were unable to conduct a restricted analysis for this group.   
Estimates were stable in sensitivity analyses exploring alternative model specifications, with 
estimates for holding regimens or TI being more sensitive to model specifications given their 
smaller sample sizes (not published).   
Discussion 
This collaborative analysis of almost 1000 children with VF from eight South African cohorts 
showed that switching to second-line cART results in the best immunologic and virologic 
outcomes.  The relative immunologic benefits and risks of using holding regimens was 
quantified; for patients with VF on NNRTI-based first-line, switching to a holding regimen may 
be better than TI, but has worse outcomes than remaining on failing first-line, while switching to 
LPV/r-based second-line cART, if available and where adherence is addressed, has the best 
outcomes. 
To our knowledge, this is the first study comparing management strategies for children with VF 
from sub-Saharan Africa, where the burden of pediatric HIV is highest, and treatment options 
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most limited. This study also represents the best comparative data on the use of holding 
regimens.  Our estimates are likely conservative and potentially underestimate the true effect size 
for two reasons:  (i) we considered immunologic and virologic trajectories from “baseline” 
measurements taken at VF, however most patients first spent time on their failing regimen before 
switching strategies; (ii) we assumed patients were adherent to their assigned strategies, but 
misclassification of strategy may have occurred, with unrecorded TI being most likely. Since VL 
monitoring for patients on non-cART regimens is not routinely performed, our virologic results 
for holding regimens and TI have very wide confidence intervals. Apart from VL as a proxy 
measure, no adherence data was available. Adherence is likely a key consideration of 
management strategy choice and hence there may be unmeasured residual confounding.  We had 
no data on drug resistance mutations, and could not assess its effect on immunologic and 
virologic trajectories.  Remaining on failing NNRTI-based cART, runs a higher risk of 
accumulating drug resistance(19) compared to remaining on failing PI-based cART, where 
resistance is less likely unless there has been exposure to unboosted PI treatment.(20) Outcomes 
of remaining on failing regimens may therefore differ depending on regimen.  
Our results are largely in agreement with Fairlie et al’s study which was of similar design. They 
found switching to new cART had better immunologic outcomes compared to remaining on a 
failing regimen, with TI having the worst outcomes. Conclusions about their drug-sparing group 
could not be reached due to small numbers and large variety in the drug-sparing regimens 
used.(11) Clinician’s decision-making of management strategy may not be comparable to our 
study, since treatment options, availability of resistance testing and resistance patterns were 
likely different for the mostly heavily treatment–experienced US-based study population.  
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Compared to TI, switching to a holding regimen resulted in smaller increases in VL, and for 
those on NNRTI-based first-line, much smaller immune decline. Whilst there are few 
comparative studies addressing holding regimens in children and adolescents, there is evidence 
in adults that LM has better immunologic and virologic outcomes than TI.(21) The IMPAACT 
P1094 study enrolled children failing non-NNRTI-based cART, and aimed to compare outcomes 
of those randomized to continue with failing non-NNRTI-based cART versus changing to either 
lamivudine or emtricitabine monotherapy. The study was discontinued due to lack of enrolment, 
but the available data indicates greater immune decline for those on holding regimens.(22) 
Descriptive studies of LM use found that most children experience substantial immune decline 
and some experience clinical deterioration, and recommend avoiding this strategy in those with 
low CD4 counts, and considering it only whilst awaiting second- or third-line drugs.(7, 23)   
Understanding the virologic and immunologic consequences of TI provides a useful benchmark 
for comparison. Planned TI is recommended in some countries for children to preserve future 
cART options, avoid long-term ART toxicity and because of difficulties in maintaining 
adherence.(24) Whilst this approach is severely detrimental in adults, outcomes are better among 
younger children or those with higher nadir CD4%.(25, 26) Unplanned TI, a consequence of 
poor or non-adherence to treatment, often occurs at a poorer clinical and immunological state, 
and increases the risk of AIDS-defining illness and hospitalization.(25) We could not determine 
the reason for TI in our study, but those interrupting treatment had the highest VL at VF, 
suggesting unplanned TI in those non-adherent. Several studies among children with planned TI, 
who were virally suppressed with high CD4, as well as those with unplanned TI, have 
documented rapid immune decline and virologic rebound in a similar range to our findings,(10, 
25-28) although estimates have great inter-subject variability.  
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In conclusion, switching to second-line results in the best immunologic and virologic outcomes 
for children with VF. Where children are failing NNRTI-based cART and PI-based regimens are 
accessible, strong consideration should be given to early switch to second-line. Switching to 
holding regimens should be carefully considered, and reserved for use whilst awaiting access to 
suitable regimens. The most appropriate management strategy choice requires consideration of 
the available future treatment options and current adherence. Our findings inform that choice by 
quantifying the relative immunologic and virologic costs of delayed switching, holding regimens 
and TI in comparison to switching to second-line.  
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Figure Legend: 
Figure 1. Management Strategies followed from Virologic Failure during follow-up 
Figure 2. Estimated change in CD4% and log viral load at 12 months after virologic failure from 
crude, unweighted and weighted generalized linear models 
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Table 1.  Standard First-line Antiretroviral Therapy Regimens for HIV-infected Children in South Africa 2004-2012 
 
 
Before 2007 2007-2010 After 2010 
Co-infected with tuberculosis Stavudine, Lamivudine, Ritonavir Stavudine, Lamivudine, LPV/r + Ritonavir Abacavir, Lamivudine, LPV/r + Ritonavir  
Less than 6 months old Stavudine, Lamivudine, Ritonavir Stavudine, Lamivudine LPV/r Abacavir, Lamivudine, LPV/r 
Less than 3 years old or less than 10 kg Stavudine, Lamivudine, LPV/r Stavudine, Lamivudine, LPV/r Abacavir, Lamivudine, LPV/r 
Older than 3 years old and more than 10kg Stavudine, Lamivudine, Efavirenz Stavudine, Lamivudine, Efavirenz Abacavir, Lamivudine, Efavirenz 
LPV/r: Lopinavir/ritonavir 
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Table 2. Associations with Management Strategy Choice in Children with Virologic Failure, Relative to Remaining on a 
Failing Regimen 
 
 
aHR (95% CI)* 
Characteristics at virologic failure 
Switch to second-
line 
Switch to holding 
regimen 
Treatment 
interruption   
Type of first-line regimen (NNRTI-based vs PI-based) 8.86 (5.96-13.18) 3.18 (1.95-5.18) 1.87 (1.28-2.73) 
Gender (female vs male) 0.81 (0.65-1.01) 0.83 (0.58-1.20) 1.13 (0.86-1.48) 
Calendar year of ART start 1.06 (0.99-1.13) 1.32 (1.19-1.46) 1.10 (1.02-1.19) 
Type of facility (primary vs secondary/tertiary) 2.97 (1.99-4.44) 2.73 (1.31-5.69) 22.78 (5.62-92.31) 
Age in years at failure 1.07 (1.01-1.13) 0.95 (0.85-1.06) 1.20 (1.12-1.28) 
Viral load at failure (copies/ml) 
 
  
1000-5000 1 1 1 
5000-10000 1.73 (0.80-3.75) 1.25 (0.43-3.69) 3.18 (1.06-9.52) 
10000-50000 1.63 (0.77-3.46) 2.72 (1.06-6.95) 5.72 (2.42-13.50) 
>50000 1.45 (0.68-3.10) 0.44 (0.16-1.16) 5.93 (2.54-13.84) 
Viral load at failure x Age in years at failure 
 
  
VL >1000 and VL<5000 x Age at failure 1 1 1 
VL>=5000 and VL <10000 x Age at failure 0.95 (0.88-1.03) 0.99 (0.86-1.14) 0.76 (0.67-0.86) 
VL>=10000 and VL <50000 x Age at failure 0.95 (0.88-1.02) 0.86 (0.75-0.99) 0.82 (0.75-0.89) 
VL>=50000 x Age at failure 0.94 (0.87-1.01) 1.08 (0.95-1.22) 0.74 (0.68-0.82) 
Time-varying covariates 
 
  
Current Log10VL (per 1 Log10 increase) 1.58 (1.38-1.79) 2.33 (1.89-2.88) 2.18 (1.89-2.52) 
*Hazard ratios derived from pooled unweighted multinomial logistic regression fit on subsample of person-weeks of follow-up during which a switch 
to new regimen had not yet occurred  
aHR: adjusted hazard ratio 
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Figure 1 
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Figure 2 
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